News
These include the launch of a joint Pfizer UTC business, sales growth of at least 5% per year and adjusted operating profit - at least 10% in 2021-2026, global sales of 33 billion pounds ($ 46 billion), the introduction of a vaccine against respiratory syncytial virus and the drug Blenrep for the treatment of multiple myeloma. The future industry leader is expected to take first place in the UTS market in the United States and second in China.
More details:
https://bit.ly/3wPQJ12